Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 10.3% – Still a Buy?

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shot up 10.3% during trading on Thursday . The company traded as high as $52.25 and last traded at $52.9810. 293,962 shares changed hands during mid-day trading, a decline of 63% from the average session volume of 797,129 shares. The stock had previously closed at $48.03.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. HC Wainwright boosted their target price on Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Wedbush reissued an “outperform” rating and set a $46.00 price target on shares of Dianthus Therapeutics in a research report on Monday, December 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday. Finally, Truist Financial lifted their price target on shares of Dianthus Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Dianthus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $64.43.

Dianthus Therapeutics Stock Performance

The company has a market capitalization of $2.24 billion, a price-to-earnings ratio of -15.04 and a beta of 1.55. The firm has a 50-day simple moving average of $42.71 and a two-hundred day simple moving average of $33.92.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.11). Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%.The business had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.58 million. As a group, equities analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Simrat Randhawa sold 109,031 shares of the company’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the sale, the executive vice president owned 4,000 shares of the company’s stock, valued at approximately $152,560. This represents a 96.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Ryan Savitz sold 20,000 shares of the stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $45.18, for a total value of $903,600.00. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 216,538 shares of company stock worth $8,283,175. 8.15% of the stock is owned by company insiders.

Institutional Investors Weigh In On Dianthus Therapeutics

Several large investors have recently bought and sold shares of the stock. Parkside Financial Bank & Trust boosted its stake in shares of Dianthus Therapeutics by 131.7% in the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock valued at $37,000 after buying an additional 540 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Dianthus Therapeutics by 4.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after buying an additional 618 shares during the period. Bessemer Group Inc. raised its holdings in Dianthus Therapeutics by 7.8% in the third quarter. Bessemer Group Inc. now owns 16,134 shares of the company’s stock valued at $635,000 after acquiring an additional 1,170 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Dianthus Therapeutics in the second quarter worth approximately $27,000. Finally, Russell Investments Group Ltd. purchased a new position in Dianthus Therapeutics in the third quarter worth approximately $64,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.